These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27627691)

  • 1. Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.
    Tramutola A; Di Domenico F; Barone E; Arena A; Giorgi A; di Francesco L; Schininà ME; Coccia R; Head E; Butterfield DA; Perluigi M
    Antioxid Redox Signal; 2017 Mar; 26(7):280-298. PubMed ID: 27627691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly-ubiquitin profile in Alzheimer disease brain.
    Tramutola A; Triani F; Di Domenico F; Barone E; Cai J; Klein JB; Perluigi M; Butterfield DA
    Neurobiol Dis; 2018 Oct; 118():129-141. PubMed ID: 30003951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.
    Di Domenico F; Coccia R; Cocciolo A; Murphy MP; Cenini G; Head E; Butterfield DA; Giorgi A; Schinina ME; Mancuso C; Cini C; Perluigi M
    Biochim Biophys Acta; 2013 Aug; 1832(8):1249-59. PubMed ID: 23603808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.
    Perluigi M; Di Domenico F; Buttterfield DA
    Proteomics Clin Appl; 2014 Feb; 8(1-2):73-85. PubMed ID: 24259517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.
    Cenini G; Fiorini A; Sultana R; Perluigi M; Cai J; Klein JB; Head E; Butterfield DA
    Free Radic Biol Med; 2014 Nov; 76():89-95. PubMed ID: 25151119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.
    Di Domenico F; Pupo G; Tramutola A; Giorgi A; Schininà ME; Coccia R; Head E; Butterfield DA; Perluigi M
    Free Radic Biol Med; 2014 Jun; 71():270-280. PubMed ID: 24675226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome.
    Tramutola A; Lanzillotta C; Di Domenico F; Head E; Butterfield DA; Perluigi M; Barone E
    Neurobiol Dis; 2020 Apr; 137():104772. PubMed ID: 31987911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics.
    Di Domenico F; Barone E; Perluigi M; Butterfield DA
    Antioxid Redox Signal; 2017 Mar; 26(8):364-387. PubMed ID: 27626216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.
    Butterfield DA; Di Domenico F; Swomley AM; Head E; Perluigi M
    Biochem J; 2014 Oct; 463(2):177-89. PubMed ID: 25242166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome.
    Di Domenico F; Tramutola A; Barone E; Lanzillotta C; Defever O; Arena A; Zuliani I; Foppoli C; Iavarone F; Vincenzoni F; Castagnola M; Butterfield DA; Perluigi M
    Redox Biol; 2019 May; 23():101162. PubMed ID: 30876754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease.
    Tramutola A; Di Domenico F; Barone E; Perluigi M; Butterfield DA
    Oxid Med Cell Longev; 2016; 2016():2756068. PubMed ID: 26881020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant protein expression of transcription factors BACH1 and ERG, both encoded on chromosome 21, in brains of patients with Down syndrome and Alzheimer's disease.
    Shim KS; Ferrando-Miguel R; Lubec G
    J Neural Transm Suppl; 2003; (67):39-49. PubMed ID: 15068237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome.
    Martínez-Cué C; Rueda N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterising the brain metalloproteome in Down syndrome patients with concomitant Alzheimer's pathology.
    Malakooti N; Roberts B; Pritchard MA; Volitakis I; Kim RC; Lott IT; McLean CA; Finkelstein DI; Adlard PA
    Metallomics; 2020 Jan; 12(1):114-132. PubMed ID: 31764918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology.
    Seidl R; Cairns N; Singewald N; Kaehler ST; Lubec G
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):139-45. PubMed ID: 11218066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.
    Wegiel J; Flory M; Kuchna I; Nowicki K; Wegiel J; Ma SY; Zhong N; Bobrowicz TW; de Leon M; Lai F; Silverman WP; Wisniewski T
    Acta Neuropathol Commun; 2022 Jan; 10(1):2. PubMed ID: 34983655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.
    Hamlett ED; Boger HA; Ledreux A; Kelley CM; Mufson EJ; Falangola MF; Guilfoyle DN; Nixon RA; Patterson D; Duval N; Granholm AC
    Curr Alzheimer Res; 2016; 13(1):35-52. PubMed ID: 26391050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.
    Tramutola A; Pupo G; Di Domenico F; Barone E; Arena A; Lanzillotta C; Brokeaart D; Blarzino C; Head E; Butterfield DA; Perluigi M
    J Alzheimers Dis; 2016; 52(1):359-371. PubMed ID: 26967221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down syndrome and Alzheimer's disease: a link between development and aging.
    Lott IT; Head E
    Ment Retard Dev Disabil Res Rev; 2001; 7(3):172-8. PubMed ID: 11553933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.